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About  tolerance  to  the  antibiotic  prescribed,  84.8%
(n  = 28)  of  patients  did  not  experience  any  side  effects  asso-
ciated  with  the  drug;  however,  5  patients  (15.2%)  required
its  suspension  due  to  headache,  upper  abdominal  pain  and
oral  clefts.
All  antibiotics  prescribed  regimens  produced  a  reduc-
tion  in  sputum  volume  and  there  was  no  development  of
highly  resistant  strains  throughout  the  study,  the  inhaled
antimicrobial  therapy  did  not  change  the  microorganisms’
sensitivity  proﬁle.
In  the  literature  several  studies  showed  similar  results,
clinical  improvement,  lower  risk  of  acute  exacerbations
and  risk  reduction  of  unscheduled  admissions  in  patients
on  inhaled  antibiotic  therapy.  In  Portugal,  epidemiological
studies  are  scarce,  with  results  mainly  in  ventilator-
associated  pneumonia.
Although  the  data  collected  was  only  from  patients  fol-linical and functional impact
f inhaled antibiotics in a
ortuguese Pulmonology
epartment
o  the  Editor,
hronic  infection  by  gram-negative  agents  is  associated  with
rogressive  deterioration  of  lung  function  and  clinical  wors-
ning  of  patients  with  respiratory  disease.1
Inhaled  antibiotics  have  been  effectively  administered
ith  safety  and  efﬁcacy  in  these  patients,  particular  in  cystic
brosis,  bronchiectasis  and  in  the  prevention  and  treatment
f  patients  with  pneumonia,  with  promising  results.2--4
Chronic  suppressive  therapy,  the  proactive  use  of  an
ntibiotic  regimen  rather  than  the  reactive  use  of  antibiotics
ollowing  patient  deterioration,  has  become  the  standard  of
are  over  the  last  decade.5
Inhaled  antimicrobial  therapy  is  frequently  used  in
hronic  suppressive  regimens,  and  has  the  advantage  of  tar-
eting  the  site  of  infection  and  achieving  higher  antibiotic
putum  concentrations  within  the  airway  surface  liquid  than
ntravenous  antibiotics.6,7
Here,  the  authors  evaluate  the  efﬁcacy  and  safety
f  inhaled  antibiotics,  as  continued  and  support  therapy,
or  patients  with  respiratory  disease  chronically  colonized
ith  Pseudomonas  aeruginosa, determine  if  the  admin-
stration  of  antimicrobials  in  the  respiratory  tract  was
ssociated  with  clinical  and  functional  improvement  in
hese  patients  and  also  veriﬁed  if  the  administration  of
nhaled  antibiotics  changes  the  microorganisms’  sensitivity
roﬁle.
We  retrospectively  analyzed  the  demographic  and  clini-
al  characteristics  of  patients  who  inhaled  antibiotics  during
013  in  the  Pulmonology  Department  of  Centro  Hospitalar  de
ão  João,  a  hospital  in  the  northern  region  of  Portugal,  as
ell  as  evaluated  the  functional  differences  and  the  sensi-
ivity  proﬁle  in  the  6  months  before  and  after  initiation  of
nhaled  therapy.A total  of  33  patients  were  on  inhaled  antibiotics
uring  this  period,  54.5%  (n  =  18)  were  male  and  45.5%
n  =  15)  female,  with  an  average  age  of  35  years  (25--54
ears).  Of  these  patients,  54.5%  (n  =  18)  had  cystic  ﬁbrosis,
4.2%  (n  =  8)  bronchiectasis,  12.1%  (n  =  4)  were  trans-
lanted  lung,  6.1%  (n  =  2)  diffuse  pulmonary  disease  and  3%
n  =  1)  had  amyotrophic  lateral  sclerosis.  Inhaled  colistin
l
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sas  prescribed  in  54.5%  (n  =  18)  of  patients,  tobramycin
n  42.4%  (n  =  14)  and  aztreonam  in  one  patient.  We
ound  overlapping  in  the  pre-and  post-treatment  func-
ional  assessment  (FEV1: 45.9  ±  19.6%  vs.  47.2  ±  20.7%,
 = 0.43;  FVC:  68.8  ±  20.4%  vs.  69.4  ±  21.5%,  p  =  0.75,  IT:
6.1  ±  15.3%  vs.  55.7  ±  14.9%,  p  =  0.71).  Nevertheless,
onsidering  the  different  pathologies  as  cystic  ﬁbrosis  or
on-cystic  ﬁbrosis,  statistically  signiﬁcant  post  treatment
unctional  differences  were  observed  (FEV1:  54.77  ±  20.61%
s.  39.08  ±  18.16%,  p  =  0.038;  FVC:  76.97  ±  24.25%  vs.
1.29  ±  14.99%,  p  =  0.046).  Comparing  the  groups  of  the
wo  most  prescribed  antibiotics,  there  were  no  clinical  and
unctional  signiﬁcant  differences.
Signiﬁcant  clinical  improvement  was  observed,  with  a
eduction  in  the  number  of  exacerbations  and  hospital-
zations,  6 months  after  the  start  of  inhaled  antibiotic
herapy  (number  of  exacerbations:  1.94  ±  0.9  vs.  0.82  ±  0.6,
 < 0.001,  number  of  hospital  admissions:  1.03  ±  1.5  vs.
.45  ±  0.8,  p =  0.002).  The  reduction  in  the  number  of  exa-
erbations  was  more  evident  in  the  group  non-cystic  ﬁbrosis
han  in  the  cystic  ﬁbrosis  patients,  and  this  difference
as  statistically  signiﬁcant  (0.6  ±  0.632  vs.  1.0  ±  0.485,
 = 0.048,  respectively).owed  in  the  Pulmonology  outpatient  clinic,  therefore  it  is
ot  representative  of  the  all  population,  the  results  support
he  beneﬁt  of  inhaled  antibiotics,  in  maintenance  regime,
o  reduce  the  number  of  admissions  and  exacerbations  in
atients  with  colonization  by  P.  aeruginosa, without  devel-
pment  of  resistant  strains  and,  in  most  patients,  without
ide  effects.
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The  present  study  showed  that  inhaled  antimicrobial
therapy  is  an  attractive  alternative  to  systemic  admin-
istration  because  it  is  associated  with  main  advantages
such  as  ability  to  achieve  high  concentrations  of  antimi-
crobials  in  sputum  and  in  the  bronchial  and  pulmonary
tissue;  and  ability  to  reach  minimum  inhibitory  con-
centrations  at  lower  dosages  compared  with  intravenous
formulations.
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Systemic adverse events from
inhaled corticosteroids
self-reported by asthma
patients: A ‘‘real-life’’ cross
sectional study
Current  guidelines  recommend  the  use  of  inhaled  corticoste-
roids  (ICS)  for  patients  with  moderate  to  severe  persistent
asthma  treatment  maintenance.1 However,  the  use  of  high
doses  for  long  periods  potentially  increase  systemic  adverse
events.2,3 A  disconnection  between  clinician  estimates  of
ICS  side  effects  and  the  prevalence  reported  by  patients  has
previously  been  reported.4 Furthermore,  there  is  evidence
that  many  asthmatic  patients  prefer  not  to  discuss  or  spon-
taneously  report  their  concerns  regarding  ICS  adverse  events
with  their  health  care  professionals.5,6 The  self-reported
questionnaires  provide  an  efﬁcient  method  of  accessing
information  about  adverse  events.7,8 We  describe  systemic
adverse  events  associated  with  the  use  of  ICS  in  patients
with  moderate  to  severe  asthma  using  this  technique.
Subjects  included  were  18  or  older,  had  moderate  or
severe  persistent  asthma,1 had  been  regularly  using  ICS  for  6
or  more  months  between  June  of  2010  and  February  of  2011
and  presented  at  the  Pharmaceutical  Assistance  Service  of
the  Pneumology  Reference  Outpatient  Clinic  of  the  Federal
University  of  Bahia,  in  Salvador,  Bahia.  Patients  taking  oral,
parenteral,  ocular  or  topical  corticosteroids  within  the  pre-
vious  three  months  were  excluded.
A  pilot  study  assessing  questionnaire  structure,  content
captured  patient’s  perceptions  regarding  the  ICS  systemic
adverse  events  (dry  skin,  swollen  face,  easy  bruising,  mood
swings,  night  sweating,  brittle  breaking  nails,  hair  loss  and
affected  vision).  The  total  score  ranged  from  0  (no  percep-
tion  of  events)  to  24  (maximum),  this  score  was  standardized
to  score  from  0  (no  events)  to  100  (worst).
The  difference  in  the  intensity  of  systemic  adverse  events
between  the  two  dosage  groups  in  relation  to  the  total  score
(accumulated)  was  analyzed  using  t-test.  The  correlation
between  duration  of  ICS  use  and  the  number  of  systemic
adverse  events  was  assessed  by  using  the  Spearman  Rho
correlation  coefﬁcient.
Of  the  65  patients  who  were  evaluated,  54  (83.1%)  were
female,  with  an  average  age  of  49.7  [SD  =  12.2]  years.  Of
the  total,  29  (44.6%)  patients  were  taking  high  doses  of  ICS
(budesonide  >  800  mcg/day),  where  the  median  daily  dose  of
ICS  was  800  mcg.  The  average  treatment  duration  was  38.2
[30.7]  months.  Sixty  (92.3%)  patients  reported  at  least  one
systemic  adverse  event,  and  31  (47.7%)  patients  reported
daily  symptoms.  A  total  of  213  events  were  reported  with  a
median  of  3.0  per  patient  (Table  1).
All  patients  were  taking  ICS  plus  long-acting  2-agonist
(87.7%  formoterol  plus  budesonide,  12.3%  salmeterol  plus
ﬂuticasone).  Thirty-six  (55.4%)  patients  received  treatment
consistent  with  moderate  asthma  and  29  (44.6%)  received
high-intensity  treatment,  consistent  with  severe  asthma.
Demographic  characteristics  were  similar  between  the  two
groups.  The  prevalence  of  vision  disturbances  and  dry  skin
was  greater  in  the  high-intensity  treatment  group  (p  <  0.05)
suggesting  a  causal  relationship.  Asthma  severity  (r  =  0.274;and  clarity  generated  data  for  an  expert  team  who  reviewed
results  and  suggested  changes.  The  self-report  question-
naire,  covered  the  previous  14  days  using  a  4-point  Likert
scale  (0  =  never;  1  =  occasionally;  2  =  most  days;  3 =  daily)  and
p
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m =  0.027)  and  ICS  use  duration  (r  =  0.361;  p  =  0.003)  were
orrelated  with  the  number  of  systemic  adverse  events.  Fur-
hermore,  patients  who  used  ICS  for  longer  periods  reported
ore  face  swelling  (p  =  0.04)  and  dry  skin  (p  = 0.002).
